HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-mar

Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-mar

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'

Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clin

Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and cli

Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinica

Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in no

Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-m

Nexalin reports Brazil trial gains in anxiety, depression and sleep, plus U.S. patent protection thr

The United States Patent and Trademark Office has issued U.S. Patent No. 12,629,519, titled: "Tr

Newly issued U.S. patent expected to provide core intellectual property protection through 2042, fur

The U.S. House of Representatives-approved report language, which was secured through the Company&#3

U.S. House Appropriations Committee report language directs VA to support additional research evalua

Through the transaction, Nexalin has secured ownership of PONM and an exclusive license to the propr

Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture

The study, titled: "Modulating Default and Salience/Ventral Attention networks: Exploring the tr

Publication reports statistically significant improvement in sleep quality following treatment with

Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in no

160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submi

HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company

ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on A

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline

BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and

Nexalin study shows reduced self-injury and depression in adolescents using DIFS, with brain connect

Nexalin Technology (NASDAQ: NXL - Get Free Report) and Algorhythm (NASDAQ: RIME - Get Free Report) a

Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report) saw a significant decline in short interest

Nexalin Technology (NASDAQ:NXL) reported quarterly losses of $(0.13) per share which missed the anal

150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lin

Nexalin advances a 150-patient U.S. insomnia trial for HALO Clarity, supporting its planned FDA subm

The pivotal study to support Nexalin's planned FDA submission builds on Nexalin's previously

Nexalin Participates in & Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulat

New digital health platform being launched in partnership with UCSD allows remote physician-monitore

Nexalin launched its AI-powered NeuroCare virtual clinic with UC San Diego, enabling at-home brain t

Nexalin launched its AI-powered NeuroCare virtual clinic with UC San Diego, enabling at-home brain t

New digital health platform being launched in partnership with UCSD allows remote physician-monitore

HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”

Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in no

Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report)'s stock price traded up 1% during trading o